The latest price target for Zenas BioPharma (NASDAQ:ZBIO) was reported by Citigroup on March 17, 2026. The analyst firm set a price target for $41.00 expecting ZBIO to rise to within 12 months (a possible 98.74% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Zenas BioPharma (NASDAQ:ZBIO) was provided by Citigroup, and Zenas BioPharma maintained their buy rating.

There is no last upgrade for Zenas BioPharma

The last downgrade for Zenas BioPharma Inc happened on January 6, 2026 when Morgan Stanley changed their price target from $37 to $19 for Zenas BioPharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zenas BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zenas BioPharma was filed on March 17, 2026 so you should expect the next rating to be made available sometime around March 17, 2027.

While ratings are subjective and will change, the latest Zenas BioPharma (ZBIO) rating was a maintained with a price target of $43.00 to $41.00. The current price Zenas BioPharma (ZBIO) is trading at is $20.63, which is out of the analyst’s predicted range.